Biotech News

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Larimar Therapeutics (LRMR)Larimar TherapeuticsEarnings

In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of

Related news

Larimar Therapeutics

Intracellular Protein Delivery Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin. Nomlabofusp Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the...

Recent company news

Stock data

Close
4.18 USD
Market cap
342.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States